{"id":405075,"date":"2025-08-18T00:04:32","date_gmt":"2025-08-17T22:04:32","guid":{"rendered":"https:\/\/medizinonline.com\/inhibition-ciblee-de-met-apres-progression-sous-osimertinib\/"},"modified":"2025-07-14T17:34:21","modified_gmt":"2025-07-14T15:34:21","slug":"inhibition-ciblee-de-met-apres-progression-sous-osimertinib","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/inhibition-ciblee-de-met-apres-progression-sous-osimertinib\/","title":{"rendered":"Inhibition cibl\u00e9e de MET apr\u00e8s progression sous osimertinib"},"content":{"rendered":"\n<p><strong>Malgr\u00e9 le succ\u00e8s de l&#8217;osimertinib, un EGFR-TKI de troisi\u00e8me g\u00e9n\u00e9ration, dans le traitement de premi\u00e8re ligne, le traitement du NSCLC apr\u00e8s progression reste un d\u00e9fi. SAVANNAH et ORCHARD ont \u00e9tudi\u00e9 l&#8217;ajout cibl\u00e9 d&#8217;autres agents \u00e0 l&#8217;osimertinib apr\u00e8s la progression de la maladie sous traitement de premi\u00e8re ligne par l&#8217;osimertinib. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Finhibition-ciblee-de-met-apres-progression-sous-osimertinib%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Malgr\u00e9 le succ\u00e8s de l&#8217;osimertinib, un EGFR-TKI de troisi\u00e8me g\u00e9n\u00e9ration, dans le traitement de premi\u00e8re ligne, le traitement du NSCLC apr\u00e8s progression reste un d\u00e9fi. SAVANNAH et ORCHARD ont \u00e9tudi\u00e9&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Finhibition-ciblee-de-met-apres-progression-sous-osimertinib%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":405078,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Th\u00e9rapie de pr\u00e9cision","footnotes":""},"category":[11527,11389,11477,11535,11549],"tags":[13157,84197,84182,13765,31042,84196],"powerkit_post_featured":[],"class_list":["post-405075","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-oncologie","category-pneumologie-fr","category-rapports-de-congres","category-rx-fr","tag-cancer-du-poumon","tag-egfr-tki-fr","tag-elcc-2025-fr","tag-nsclc-fr","tag-recidive","tag-therapie-de-precision","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-03 09:39:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":405043,"slug":"inibizione-mirata-di-met-dopo-progressione-con-osimertinib","post_title":"Inibizione mirata di MET dopo progressione con osimertinib","href":"https:\/\/medizinonline.com\/it\/inibizione-mirata-di-met-dopo-progressione-con-osimertinib\/"},"pt_PT":{"locale":"pt_PT","id":405037,"slug":"inibicao-especifica-da-met-apos-progressao-com-osimertinib","post_title":"Inibi\u00e7\u00e3o espec\u00edfica da MET ap\u00f3s progress\u00e3o com osimertinib","href":"https:\/\/medizinonline.com\/pt-pt\/inibicao-especifica-da-met-apos-progressao-com-osimertinib\/"},"es_ES":{"locale":"es_ES","id":404998,"slug":"inhibicion-dirigida-de-met-tras-progresion-con-osimertinib","post_title":"Inhibici\u00f3n dirigida de MET tras progresi\u00f3n con osimertinib","href":"https:\/\/medizinonline.com\/es\/inhibicion-dirigida-de-met-tras-progresion-con-osimertinib\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/405075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=405075"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/405075\/revisions"}],"predecessor-version":[{"id":405079,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/405075\/revisions\/405079"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/405078"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=405075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=405075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=405075"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=405075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}